Vanda Pharmaceuticals (VNDA) Net Income Growth (1y) (2011 - 2026)

Vanda Pharmaceuticals (VNDA) Net Income Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -0.46%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 63.48%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Vanda Pharmaceuticals 310.98 Mn 108.67 Mn 48.56 Mn -64.52%

Historic Data

Download Data
DateValue
Mar 31, 2026 -64.52%
Dec 31, 2025 -2,795.55%
Sep 30, 2025 -322.72%
Jun 30, 2025 -501.75%
Mar 31, 2025 -611.38%
Dec 31, 2024 -103.93%
Sep 30, 2024 -4,000.73%
Jun 30, 2024 -402.82%
Mar 31, 2024 -228.44%
Dec 31, 2023 -134.85%
Sep 30, 2023 -95.80%
Jun 30, 2023 -42.39%
Mar 31, 2023 149.94%
Dec 31, 2022 -3.07%
Sep 30, 2022 -57.77%
Jun 30, 2022 -73.17%
Mar 31, 2022 -174.73%
Dec 31, 2021 -13.75%
Sep 30, 2021 29.85%
Jun 30, 2021 11.09%